Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...

Nemaura Medical Announces SFDA Approval of sugarBEAT® Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...

Nemaura Medical Launches Metabolic Health Program for Employers and Insurers Launch into commercial markets offers opportunities for faster and wider adoption of Miboko program Loughborough, England, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)...

Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update Loughborough, England, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...

Nemaura Medical Launches Beta Version of Its Metabolic Health Program MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE...